Long-term data further supporting the efficacy and safety profile of RINVOQ with moderate to severe atopic dermatitis.
AbbVie today announced new data analyses from the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies that further demonstrated the long-term efficacy and safety profile of RINVOQ® (upadacitinib) among adults and adolescents 12 years and older…